331 related articles for article (PubMed ID: 2110012)
1. 2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity.
Foster SJ; Bruneau P; Walker ER; McMillan RM
Br J Pharmacol; 1990 Jan; 99(1):113-8. PubMed ID: 2110012
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
[TBL] [Abstract][Full Text] [Related]
3. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
Tateson JE; Randall RW; Reynolds CH; Jackson WP; Bhattacherjee P; Salmon JA; Garland LG
Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids.
Moroney MA; Alcaraz MJ; Forder RA; Carey F; Hoult JR
J Pharm Pharmacol; 1988 Nov; 40(11):787-92. PubMed ID: 2907559
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
Marshall PJ; Griswold DE; Breton J; Webb EF; Hillegass LM; Sarau HM; Newton J; Lee JC; Bender PE; Hanna N
Biochem Pharmacol; 1991 Jul; 42(4):813-24. PubMed ID: 1907824
[TBL] [Abstract][Full Text] [Related]
7. Failure of the inhibition of rat gastric mucosal 5-lipoxygenase by novel acetohydroxamic acids to prevent ethanol-induced damage.
Boughton-Smith NK; Whittle BJ
Br J Pharmacol; 1988 Sep; 95(1):155-62. PubMed ID: 3146394
[TBL] [Abstract][Full Text] [Related]
8. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
Ku EC; Raychaudhuri A; Ghai G; Kimble EF; Lee WH; Colombo C; Dotson R; Oglesby TD; Wasley JW
Biochim Biophys Acta; 1988 Apr; 959(3):332-42. PubMed ID: 2833314
[TBL] [Abstract][Full Text] [Related]
10. SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
Griswold DE; Marshall PJ; Webb EF; Godfrey R; Newton J; DiMartino MJ; Sarau HM; Gleason JG; Poste G; Hanna N
Biochem Pharmacol; 1987 Oct; 36(20):3463-70. PubMed ID: 2823821
[TBL] [Abstract][Full Text] [Related]
11. FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor.
Blackham A; Griffiths RJ; Hallam C; Mann J; Mitchell PD; Norris AA; Simpson WT
Agents Actions; 1990 Jun; 30(3-4):432-42. PubMed ID: 2117338
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin.
Peters-Golden M; Shelly C
Biochem Pharmacol; 1989 May; 38(10):1589-95. PubMed ID: 2499339
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on acute inflammatory responses.
Higgs GA; Follenfant RL; Garland LG
Br J Pharmacol; 1988 Jun; 94(2):547-51. PubMed ID: 2840161
[TBL] [Abstract][Full Text] [Related]
14. 5-lipoxygenase inhibitory activity of zileuton.
Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
[TBL] [Abstract][Full Text] [Related]
15. Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.
Bruneau P; Delvare C; Edwards MP; McMillan RM
J Med Chem; 1991 Mar; 34(3):1028-36. PubMed ID: 1848292
[TBL] [Abstract][Full Text] [Related]
16. Simple procedure for measuring the pharmacodynamics and analgesic potential of lipoxygenase inhibitors.
Carey F; Haworth D; Edmonds AE; Forder RA
J Pharmacol Methods; 1988 Dec; 20(4):347-56. PubMed ID: 3145369
[TBL] [Abstract][Full Text] [Related]
17. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S
Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321
[TBL] [Abstract][Full Text] [Related]
18. The antiinflammatory action of guanabenz is mediated through 5-lipoxygenase and cyclooxygenase inhibition.
Chang J; Blazek E; Skowronek M; Marinari L; Carlson RP
Eur J Pharmacol; 1987 Oct; 142(2):197-205. PubMed ID: 3121363
[TBL] [Abstract][Full Text] [Related]
19. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
Crawley GC; Dowell RI; Edwards PN; Foster SJ; McMillan RM; Walker ER; Waterson D; Bird TG; Bruneau P; Giroaeau JM
J Med Chem; 1992 Jul; 35(14):2600-9. PubMed ID: 1321908
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
